Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


Experience in the implementation of pharmacogenetic testing in clinical practice at the administration of statin group drugs . Analysis of long -term therapy results.

[Clinical Pharmacology]
Nikolai Rumyantsev; Vladimir Kukes; Dmitry Grapov;

The prevalence of carriage of various genotypes of the SLCO1B1 gene and the possible effect of the genotypes of the SLCO1B1 gene on the effectiveness and safety of statin therapy at the hospital stage were assessed, as well as an analysis of the long-term results of the therapy. The feasibility of using pharmacogenetic testing in patients when prescribing drugs of the statin group and the main problems in their use in clinical practice are discussed.


1.Schuster H. The GALAXY Program an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme Expert. Rev. Cardiovasc. Ther. 2007;5:177-193. https://doi.org/10.1586/14779072.5.2.177
2.Ruiz Maldonado J. M., Lumbreras B., Muñoz Jimenez H., Navarrete Carranza J. M., Anza Aguirrezabala I., Pastor Valero M. A pilot study in a community pharmacy to determine the efficiency and the effectiveness of statin prescriptions. Aten Primaria. 2015;47(5):294-300. https://doi.org/10.1016/j.aprim.2014.05.016
3. Gryn S. E., Hegele R. A. Pharmacogenomics, lipid disorders, and treatment options. Clin. Pharmacol. Ther. 2014;96:36-47. https://doi.org/10.1038/clpt.2014.82
4. Canestaro W. J., Austin M. A., Thummel K. E. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet. Med. 2014;16:810-819. https://doi.org/10.1038/gim.2014.41
5. Tornio A., Vakkilainen J., Neuvonen M., Backman J. T., Neuvonen P. J., Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenetics and genomics. 2015;8(25):382-387. https://doi.org/:10.1097/fpc.0000000000000148
6. Pasanen M. K., Fredrikson H., Neuvonen P. J. Backman J. T., Neuvonen P. T. Niemi M. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin. Clinical Pharmacology & Therapeutics. 2007;82:726-733. https://doi.org/10.1038/sj.clpt.6100220
7. Brunham L. R., Lansberg P. J., Zhang L., Miao F., Carter C. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharm. J. 2012;12(3):233-237. https://doi.org/10.1038/tpj.2010.92
8. Carr D. F., O’Meara H., Jorgensen A. L., Campbell J., Hobbs M. [et al.]. SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. Clinical Pharmacology & Therapeutics. 2013;94(6):695-701. https://doi.org/10.1038/clpt.2013.161
9. Solodun M. V., Yakushin S. S. Aspects of lipid-lowering therapy with atorvastatin in patients with myocardial infarction from the perspective of personalized medicine. Racional’naya farmakoterapiya v kardiologii. – Ration. Pharmacother. Cardiol. 2015;11(1):31-35. (In Russ.)https://doi.org/10.20996/1819-6446-2015-11-1-31-35
10. Sychev D. A., Shuev G. N., Prokofiev A. B. Applied aspects of SLCO1B1 pharmacogenetic testing for predicting of statin-induced myopathy and personalization of statins therapy. Racional’naya farmakoterapiya v kardiologii. – Ration. Pharmacother. Cardiol. 2013;9(6):698-700. (In Russ.). https://doi.org/10.20996/1819-6446-2013-9-6-698-700
11. Shuev G. N., Sychev D. A., Grachev A. V. Gene polymorphism of SLCO1B1, associated with the development of statin-induced myopathy, leves of vitamin d in russian patients with hyperlipidemia. Kreativnaya kardiologiya. – Creat. Cardiology. (In Russ.). https://doi.org/10.15275/kreatkard.2015.04.05
12. Parker B. A., Capizzi J. A., Grimaldi A. S. Effect of statins on skeletal muscle function. Circulation. 2013;127:96-103. https://doi.org/10.3410/f.717969170.793516682
13. Hubáček J. A., Dlouhá D., Adámková V., Zlatohlavek L., Viklický O. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Medical science monitor: international medical journal of experimental and clinical research. 2015;21:1454-1459. https://doi.org/10.12659/msm.893007

Keywords: statins, personalized medicine, pharmacogenetics

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy